TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight

Benzinga Logo Benzinga By Vishaal Sanjay
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight

Merck & Co. is in advanced talks to acquire cancer drug-maker Revolution Medicines for $28-32 billion, marking potentially the largest biotech M&A deal since Pfizer's $43 billion Seagen acquisition in 2023. Revolution Medicines' stock surged 15.14% overnight on the news. The deal reflects Merck's acquisition strategy amid an industry patent cliff, following recent purchases of Cidara Therapeutics and Verona Pharma.

Insights
MRK   positive

Merck is actively pursuing strategic acquisitions to strengthen its cancer drug portfolio and address upcoming patent expirations, particularly for Keytruda in 2028. The deal demonstrates growth strategy and market positioning.